The BTD was granted based on the interim results of the Phase III DREAMM-7 trial, which met its primary endpoint.

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

London open The FTSE 100 is expected to open 54 points higher on Tuesday, having closed up 0.07% on Monday at 8,278.44.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

Fresnillo rose 6.5%, or 35p, to 572.5p, Centamin climbed 1.2%, or 1.9p, to 155.9p and Hochschild Mining added 3.7%, or 6.4p, ...

Find insight on GSK and more in the latest Market Talks covering the Health Care sector.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...